Search

Your search keyword '"Moris, Maria"' showing total 5 results
Start Over Author "Moris, Maria" Journal pancreas
5 results on '"Moris, Maria"'

1. Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms

Author

Moris, Maria, Dawson, David W, Jiang, Jennifer, Lewis, Jason, Nassar, Aziza, Takeuchi, Kenneth K, Lay, Anna R, Zhai, Qihui, Donahue, Timothy R, Kelly, Kimberly A, Crawford, Howard C, and Wallace, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, Digestive Diseases, Rare Diseases, Adenocarcinoma, Mucinous, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal, Humans, Pancreatic Neoplasms, Plectin, Plectin-1, intraductal papillary mucinous neoplasm, biomarker, immunohistochemistry, branch duct IPMN, malignant progression, pancreatic adenocarcinoma, Gastroenterology & Hepatology, Clinical sciences
Abstract

ObjectiveThis study aimed to evaluate Plectin-1 expression as a biomarker of malignant risk for intraductal papillary mucinous neoplasms (IPMNs).MethodsPlectin-1 immunohistochemistry (IHC) was performed retrospectively on surgical (n = 71) and cytological (n = 33) specimens from Mayo Clinic Jacksonville and UCLA Medical Center, including IPMNs with low-grade dysplasia, high-grade dysplasia (HGD), or an associated invasive adenocarcinoma.ResultsPlectin-1 expression was increased in invasive adenocarcinoma compared with adjacent in situ IPMN (P = 0.005), as well as the in situ HGD component of IPMNs with invasive cancer compared with HGD of IPMNs without invasive cancer (P = 0.02). Plectin IHC discriminated IPMNs with invasive adenocarcinoma from noninvasive IPMN (area under the curve [AUC] of 0.79, 75% sensitivity, and 85% specificity) but was insufficient for discriminating HGD IPMN from low-grade dysplasia IPMNs in surgical resections (AUC of 0.67, 56% sensitivity, and 64% specificity) or fine-needle aspiration specimens (AUC of 0.45).ConclusionsAlthough Plectin-1 IHC has insufficient accuracy to be used as a definitive biomarker for malignant risk in the evaluation of IPMN biopsy or cytological specimens, increased Plectin-1 expression observed in both invasive cancer and in situ HGD of malignant IPMNs suggests that it might be successfully leveraged as a cyst fluid biomarker or molecular imaging target.

Published
2016

3. Predictors of Progression Among Low-Risk Intraductal Papillary Mucinous Neoplasms in a Multicenter Surveillance Cohort

Author

Gausman, Valerie, primary, Kandel, Pujan, additional, Van Riet, Priscilla A., additional, Moris, Maria, additional, Kayal, Maia, additional, Do, Catherine, additional, Poneros, John M., additional, Sethi, Amrita, additional, Gress, Frank G., additional, Schrope, Beth A., additional, Luk, Lyndon, additional, Hecht, Elizabeth, additional, Jovani, Manol, additional, Bruno, Marco J., additional, Cahen, Djuna L., additional, Wallace, Michael B., additional, and Gonda, Tamas A., additional

Published
2018
Full Text
View/download PDF

4. Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology, Carcinoembryonic Antigen, and Amylase in Intraductal Papillary Mucinous Neoplasm

Author

Moris, Maria, primary, Raimondo, Massimo, additional, Woodward, Timothy A., additional, Skinner, Verna, additional, Arcidiacono, Paolo G., additional, Petrone, Maria C., additional, De Angelis, Claudio, additional, Manfrè, Selene, additional, Fusaroli, Pietro, additional, Asbun, Horacio, additional, Stauffer, John, additional, and Wallace, Michael B., additional

Published
2016
Full Text
View/download PDF

5. International Intraductal Papillary Mucinous Neoplasms Registry

Author

Selene Manfrè, Claudio De Angelis, Pietro Fusaroli, Maria Chiara Petrone, Massimo Raimondo, Silvia Carrara, Paolo Giorgio Arcidiacono, Maria Moris, Manol Jovani, Verna Skinner, Timothy A. Woodward, Michael B. Wallace, Moris, Maria, Raimondo, Massimo, Woodward, Timothy A., Skinner, Verna J., Arcidiacono, Paolo G., Petrone, Maria C., de Angelis, Claudio, Manfrè, Selene, Carrara, Silvia, Jovani, Manol, Fusaroli, Pietro, and Wallace, Michael B.

Subjects
Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Malignancy, Main duct, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, Carcinoma, medicine, Humans, Cyst, Longitudinal Studies, Registries, Aged, Gastrointestinal Neoplasms, Retrospective Studies, Hepatology, Intraductal papillary mucinous neoplasm, business.industry, Retrospective cohort study, Long term results, medicine.disease, Adenocarcinoma, Mucinous, Surgery, Pancreatic Neoplasms, Adenocarcinoma, Papillary, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, Disease Progression, Adenocarcinoma, Female, 030211 gastroenterology & hepatology, Radiology, Pancreatic Cyst, business, Carcinoma, Pancreatic Ductal, Follow-Up Studies
Abstract

OBJECTIVE: The aim of this study was to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. METHODS: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. RESULTS: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMN consisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time of more than 5 years, and no malignancy was diagnosed. CONCLUSIONS: In IPMN lesions with low-risk features at baseline, the risk of progression to malignancy after the first 5 years of follow-up was minimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results